Table 4.
Achievement of outcome indices of the Action Plan.
| Resistance Rate to Antimicrobials in Bacterial Isolates | |||
|---|---|---|---|
| Indices | 2013 | 2020 | Targets |
| Insensitive rate to penicillin in Streptococcus pneumoniae isolates | 47.4% | 33.3% | ≤15% |
| Resistance rate to fluoroquinolones in Escherichia coli isolates | 35.5% | 41.5% | ≤25% |
| Resistance rates to methicillin in Staphylococcus aureus isolates | 51.1% | 47.5% | ≤20% |
| Resistance rates to carbapenem in Pseudomonas aeruginosa isolates | 10.7–17.1% | 10.5–15.9% | ≤10% |
| Resistance rates to carbapenems in E. coli and Klebsiella pneumoniae isolates | 0.1–0.6% | 0.1–0.4% | ≤0.2% (similar level) |
| Use of Antimicrobials (Defined Daily Doses per 1000 Inhabitants per Day) | |||
| Indices | 2013 | 2020 (vs. 2013 Level) | Targets |
| Total | 14.91 | Reduction by 28.9% | ≤2/3 (vs. 2013 level) |
| Oral cephalosporins, fluoroquinolones, and macrolides | 3.91, 2.83, and 4.83, respectively | Oral cephalosporins Reduction by 42.8% Oral fluoroquinolones Reduction by 41.5% Oral macrolides Reduction by 39.5% |
Reduction by 50% (vs. 2013 level) |
| Intravenous antimicrobials | 0.96 | Reduction by 2.7% | Reduction by 20% (vs. 2013 level) |